NovoCure former CMO sells 1,029 shares for taxes

NovoCure Ltd insider Nicolas Leupin, the company’s former Chief Medical Officer, reported an open-market sale of 1,029 ordinary shares on February 27, 2026 at a weighted average price of $13.6638 per share.

Rhea-AI Filing Summary

NovoCure Ltd insider Nicolas Leupin, the company’s former Chief Medical Officer, reported an open-market sale of 1,029 ordinary shares on February 27, 2026 at a weighted average price of $13.6638 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under NovoCure’s equity incentive plans, as required by the award agreement. After this tax-related, non-discretionary “sell to cover” transaction, Leupin continued to hold 104,079 ordinary shares directly.

Insider Trade Summary

Net Seller: 1,029 shares

Net Sell 1 txn

Insider Leupin Nicolas

Role Former Chief Medical Officer

Sold 1,029 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,029	$13.6638	$14K

Holdings After Transaction: Ordinary Shares — 104,079 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
2. F2. This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NovoCure (NVCR) insider Nicolas Leupin report in this Form 4?

Nicolas Leupin reported selling 1,029 NovoCure ordinary shares on February 27, 2026. The transaction was tied to tax withholding from vesting restricted stock units, and he held 104,079 shares directly after the sale.

At what price were the 1,029 NovoCure (NVCR) shares sold by Nicolas Leupin?

The 1,029 shares were sold at a weighted average price of $13.6638 per share. Individual trades occurred in a price range from $13.45 to $13.97, according to the detailed transaction disclosure.

Why did NovoCure (NVCR) former CMO Nicolas Leupin sell 1,029 shares?

The sale was required to cover tax withholding obligations from vesting restricted stock units. NovoCure’s award agreement mandated a “sell to cover” transaction, so this was not a discretionary trade by Leupin.

How many NovoCure (NVCR) shares does Nicolas Leupin hold after this Form 4 transaction?

After the reported sale, Nicolas Leupin directly holds 104,079 NovoCure ordinary shares. This remaining balance reflects his holdings following the 1,029-share sale executed to satisfy tax withholding requirements.

Was the NovoCure (NVCR) insider sale by Nicolas Leupin an open-market transaction?

Yes, the filing characterizes the transaction as an open-market sale. However, it also specifies that the sale was mandated as a tax “sell to cover” related to restricted stock unit vesting rather than a discretionary portfolio decision.

What role does Nicolas Leupin hold at NovoCure (NVCR) in this Form 4 filing?

In this filing, Nicolas Leupin is identified as NovoCure’s former Chief Medical Officer. The reported transaction relates to equity awards and associated tax withholding from his service in that executive capacity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leupin Nicolas

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Former Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/27/2026		S		1,029(1)	D	$13.6638(2)	104,079	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Leupin, Nicolas	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.